NASDAQ:CNTA Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis $14.30 -0.30 (-2.05%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$13.83▼$14.8050-Day Range$8.58▼$14.6352-Week Range$5.15▼$14.91Volume150,556 shsAverage Volume322,729 shsMarket Capitalization$1.44 billionP/E RatioN/ADividend YieldN/APrice Target$12.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Centessa Pharmaceuticals alerts: Email Address Centessa Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside10.8% Downside$12.75 Price TargetShort InterestHealthy1.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 3 Articles This WeekInsider TradingSelling Shares$206,000 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.61) to ($1.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.34 out of 5 starsMedical Sector687th out of 910 stocksPharmaceutical Preparations Industry319th out of 426 stocks 1.4 Analyst's Opinion Consensus RatingCentessa Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCentessa Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Centessa Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.46% of the float of Centessa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCentessa Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Centessa Pharmaceuticals has recently decreased by 20.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCentessa Pharmaceuticals does not currently pay a dividend.Dividend GrowthCentessa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CNTA. Previous Next 2.3 News and Social Media Coverage News SentimentCentessa Pharmaceuticals has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Centessa Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest1 people have searched for CNTA on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Centessa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Centessa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $206,000.00 in company stock.Percentage Held by Insiders11.59% of the stock of Centessa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.01% of the stock of Centessa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Centessa Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Centessa Pharmaceuticals are expected to grow in the coming year, from ($1.61) to ($1.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Centessa Pharmaceuticals is -10.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Centessa Pharmaceuticals is -10.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentessa Pharmaceuticals has a P/B Ratio of 5.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Centessa Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankGo here to get full details on this crypto now. About Centessa Pharmaceuticals Stock (NASDAQ:CNTA)Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.Read More CNTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNTA Stock News HeadlinesAugust 28, 2024 | insidertrades.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $51,362.08 in StockAugust 24, 2024 | insidertrades.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $148,449.66 in StockSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…September 1, 2024 | americanbankingnews.comCentessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume IncreaseAugust 28, 2024 | americanbankingnews.comCentessa Pharmaceuticals (NASDAQ:CNTA) Sees Unusually-High Trading VolumeAugust 28, 2024 | americanbankingnews.comGregory M. Weinhoff Sells 12,198 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockAugust 27, 2024 | globenewswire.comCentessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)August 24, 2024 | finance.yahoo.comInsider Sale: Chief Business Officer Gregory Weinhoff Sells 30,000 Shares of Centessa ...September 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 21, 2024 | msn.comCentessa Records Small Gains Ahead of ConferenceAugust 21, 2024 | globenewswire.comCentessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 19, 2024 | finance.yahoo.comCentessa Pharmaceuticals plc's (NASDAQ:CNTA) high institutional ownership speaks for itself as stock continues to impress, up 18% over last weekAugust 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Centessa Pharmaceuticals Amid Strong Innovation and Promising Pipeline ProgressAugust 14, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Centessa Pharmaceuticals (CNTA)August 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Centessa Pharmaceuticals Amid Promising Trial Prospects and Strategic Growth InitiativesAugust 13, 2024 | globenewswire.comCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024July 24, 2024 | markets.businessinsider.comAlkermes Plc Q2 Profit Drops, Inline With EstimatesJuly 20, 2024 | seekingalpha.comKNSA Kiniksa Pharmaceuticals International, plcSee More Headlines Receive CNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTA CUSIPN/A CIK1847903 Webwww.centessa.com Phone44-73-9178-9784FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$12.75 High Stock Price Target$15.00 Low Stock Price Target$11.00 Potential Upside/Downside-10.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,090,000.00 Net MarginsN/A Pretax Margin-2,303.27% Return on Equity-63.08% Return on Assets-42.97% Debt Debt-to-Equity Ratio0.27 Current Ratio13.29 Quick Ratio13.29 Sales & Book Value Annual Sales$6.85 million Price / Sales209.67 Cash FlowN/A Price / Cash FlowN/A Book Value$2.54 per share Price / Book5.63Miscellaneous Outstanding Shares100,482,000Free Float88,836,000Market Cap$1.44 billion OptionableOptionable Beta1.44 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Saurabh Saha M.D. (Age 48)Ph.D., CEO & Director Comp: $957.67kDr. Gregory M. Weinhoff M.B.A. (Age 53)M.D., Principal Accounting Officer & CFO Comp: $655kDr. David M. Chao Ph.D. (Age 56)Chief Administrative Officer Comp: $655kMs. Tia L. Bush (Age 53)Chief Technology & Quality Officer Ms. Kristen K. Sheppard Esq.J.D., Senior Vice President of Investor Relations & Corporate CommunicationsMr. Iqbal J. Hussain L.L.B. (Age 43)General Counsel, Chief Compliance Officer & Corporate Secretary Ms. Karen M. Anderson (Age 56)Chief People Officer Dr. Antoine Yver M.D. (Age 66)M.Sc., Executive VP & Chairman of Development Comp: $449.58kDr. Harris L. Rotman Ph.D.Senior Vice President of Regulatory AffairsDr. Patrick Yue M.D.Senior VP of Clinical Development & Innovative MedicinesMore ExecutivesKey CompetitorsPrevail TherapeuticsNASDAQ:PRVLScholar RockNASDAQ:SRRKDICE TherapeuticsNASDAQ:DICEOcugenNASDAQ:OCGNRepare TherapeuticsNASDAQ:RPTXView All CompetitorsInsiders & InstitutionsSaurabh SahaSold 506 sharesTotal: $6,188.38 ($12.23/share)Gregory M WeinhoffSold 12,198 sharesTotal: $148,449.66 ($12.17/share)Saurabh SahaSold 4,169 sharesTotal: $51,362.08 ($12.32/share)Nantahala Capital Management LLCBought 450,000 shares on 8/20/2024Ownership: 0.448%Point72 Asset Management L.P.Sold 495,714 shares on 8/19/2024Ownership: 1.754%View All Insider TransactionsView All Institutional Transactions CNTA Stock Analysis - Frequently Asked Questions How have CNTA shares performed this year? Centessa Pharmaceuticals' stock was trading at $7.96 on January 1st, 2024. Since then, CNTA stock has increased by 79.6% and is now trading at $14.30. View the best growth stocks for 2024 here. How were Centessa Pharmaceuticals' earnings last quarter? Centessa Pharmaceuticals plc (NASDAQ:CNTA) issued its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by $0.02. When did Centessa Pharmaceuticals IPO? Centessa Pharmaceuticals (CNTA) raised $285 million in an initial public offering (IPO) on Friday, May 28th 2021. The company issued 15,000,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers. Who are Centessa Pharmaceuticals' major shareholders? Top institutional shareholders of Centessa Pharmaceuticals include First Light Asset Management LLC (4.76%), Perceptive Advisors LLC (3.91%), Driehaus Capital Management LLC (2.08%) and Farallon Capital Management LLC (1.99%). Insiders that own company stock include Saurabh Saha, Antoine Yver, Gregory M Weinhoff, David M Chao, Tia L Bush, Iqbal J Hussain, Thomas Templeman, Harris Rotman, Medicxi Ventures Management (J, David J Grainger, Rubertis Francesco De and Aaron Kantoff. View institutional ownership trends. How do I buy shares of Centessa Pharmaceuticals? Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CNTA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
